Asset Advisory Group’s Citius Pharmaceuticals CTXR Stock Holding History

Asset Advisory Group’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$31.3K	Hold	59,011	–	–	0.01%	120
2026 Q2	$35.7K	Hold	59,011	–	–	0.02%	124
2026 Q1	$53.1K	Hold	59,011	–	–	0.03%	115
2025 Q4	$45.9K	Buy	+59,011	New	+$73.8K	0.02%	119

Other funds holding CTXR

Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Princeton Global Asset Management Princeton, New Jersey $692M AUM 20.31% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Asset Advisory Group's CTXR Position: Q3 2026 in Review

Asset Advisory Group held its Citius Pharmaceuticals (CTXR) position steady in Q3 2026 at 59,011 shares worth $31.3K. The position accounts for 0.01% of the portfolio, ranked #120.

Asset Advisory Group first reported a position in CTXR in Q4 2025 and has held it in 4 quarters since. The position peaked at $53.1K in Q1 2026. 5 funds tracked by Wall St. Rank hold CTXR as of Q3 2026.

Asset Advisory Group held 59,011 shares of Citius Pharmaceuticals worth $31.3K as of Q3 2026.
Asset Advisory Group left its Citius Pharmaceuticals share count unchanged in Q3 2026.
Citius Pharmaceuticals made up 0.01% of Asset Advisory Group's portfolio in Q3 2026, its #120 holding.
Asset Advisory Group first reported a position in Citius Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
Asset Advisory Group's Citius Pharmaceuticals position peaked at $53.1K in Q1 2026.
5 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2026.

Based on Asset Advisory Group's 13F filing for Q3 2026, filed 20 Oct 2026.